Temitayo Ajayi

2.7k total citations · 2 hit papers
48 papers, 1.7k citations indexed

About

Temitayo Ajayi is a scholar working on Immunology, Pulmonary and Respiratory Medicine and Physiology. According to data from OpenAlex, Temitayo Ajayi has authored 48 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 10 papers in Pulmonary and Respiratory Medicine and 10 papers in Physiology. Recurrent topics in Temitayo Ajayi's work include Complement system in diseases (11 papers), Lysosomal Storage Disorders Research (10 papers) and Glycogen Storage Diseases and Myoclonus (8 papers). Temitayo Ajayi is often cited by papers focused on Complement system in diseases (11 papers), Lysosomal Storage Disorders Research (10 papers) and Glycogen Storage Diseases and Myoclonus (8 papers). Temitayo Ajayi collaborates with scholars based in United States, Germany and United Kingdom. Temitayo Ajayi's co-authors include Jeanine P. Wiener-Kronish, Teiji Sawa, Peter Slasor, Leonard R. Allmond, David Jacoby, Angela Schulz, Alfried Kohlschütter, Kiyoshi Moriyama, Heather Cahan and Nicola Specchio and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Temitayo Ajayi

46 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Study of Intraventricular Cerliponase Alfa for CLN2 Disease

2018 310 citations Angela Schulz, Temitayo Ajayi et al. profile →
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

2021 249 citations Peter Hillmen, Jeff Szer et al. profile →

Peers

Countries citing papers authored by Temitayo Ajayi

Since Specialization

Citations

This map shows the geographic impact of Temitayo Ajayi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Temitayo Ajayi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Temitayo Ajayi more than expected).

Fields of papers citing papers by Temitayo Ajayi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Temitayo Ajayi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Temitayo Ajayi. The network helps show where Temitayo Ajayi may publish in the future.

Co-authorship network of co-authors of Temitayo Ajayi

This figure shows the co-authorship network connecting the top 25 collaborators of Temitayo Ajayi. A scholar is included among the top collaborators of Temitayo Ajayi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Temitayo Ajayi. Temitayo Ajayi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Analytical prediction of genetic contribution across multiple recurrent backcrossing generations 2024 ·Theoretical and Applied Genetics ·Temitayo Ajayi, (unknown), (unknown), Trevor H. Yeats	2
2	Code and Data Repository for Combination Chemotherapy Optimization with Discrete Dosing 2023 ·INFORMS journal on computing ·Temitayo Ajayi, (unknown), Andrew J. Schaefer, Clifton D. Fuller	1
3	Combination Chemotherapy Optimization with Discrete Dosing 2023 ·INFORMS journal on computing ·Temitayo Ajayi, (unknown), Andrew J. Schaefer, Clifton D. Fuller	1
4	Evaluating mixed-integer programming models over multiple right-hand sides 2023 ·Operations Research Letters ·(unknown), Temitayo Ajayi, Andrew J. Schaefer	2
5	Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria 2023 ·Blood Advances ·Raymond Wong, (unknown), (unknown), Yeow Tee Goh, (unknown), (unknown), David Gómez‐Almaguer, Mohammed Al-Adhami, Temitayo Ajayi, (unknown), (unknown), Pascal Deschatelets, Cedric Francois, F Grossi, (unknown)	32
6	PB2053: POPULATION PHARMACOKINETICS OF PEGCETACOPLAN IN HEALTHY SUBJECTS AND PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 2023 ·HemaSphere ·(unknown), Ryan L. Crass, Sunny Chapel, Temitayo Ajayi	1
7	Dysphagia and shortness-of-breath as markers for treatment failure and survival in oropharyngeal cancer after radiation 2023 ·Radiotherapy and Oncology ·Jarey H. Wang, (unknown), Lance McCoy, (unknown), Temitayo Ajayi, Amy C. Moreno, Abdallah Mohamed, Katherine A. Hutcheson, Clifton D. Fuller, Lisanne V. van Dijk	4
8	Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial 2022 ·The Lancet Haematology ·Régis Peffault de Latour, Jeff Szer, Ilene C. Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, Kensuke Usuki, Morag Griffin, Jean‐Jacques Kiladjian, Carlos M. de Castro, Hisakazu Nishimori, Temitayo Ajayi, Mohammed Al-Adhami, Pascal Deschatelets, Cedric Francois, F Grossi, Antonio M. Risitano, Peter Hillmen	43
9	Objective Selection for Cancer Treatment: An Inverse Optimization Approach 2022 ·Operations Research ·Temitayo Ajayi, Taewoo Lee, Andrew J. Schaefer	6
10	The Gap Function: Evaluating Integer Programming Models over Multiple Right-Hand Sides 2021 ·Operations Research ·Temitayo Ajayi, Christopher Thomas, Andrew J. Schaefer	3
11	Cerliponase alfa for the treatment of CLN2 disease in an expanded patient cohort including children younger than three years: Interim results from an ongoing clinical study 2020 ·Molecular Genetics and Metabolism ·Angela Schulz, Emily de los Reyes, Nicola Specchio, Paul Gissen, Heather Cahan, Peter Slasor, Temitayo Ajayi	1
12	Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study 2018 ·Clinical Immunology ·Anu Cherukuri, Heather Cahan, (unknown), (unknown), Peter Slasor, (unknown), Joshua Henshaw, Temitayo Ajayi, (unknown), Charles O’Neill, Becky Schweighardt	25
13	Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study 2018 ·The Lancet Child & Adolescent Health ·Miriam Nickel, Alessandro Simonati, David Jacoby, Susanne Lezius, (unknown), (unknown), Odelya E. Pagovich, Barry E. Kosofsky, Kaleb Yohay, Matthew Downs, Peter Slasor, Temitayo Ajayi, Ronald G. Crystal, Alfried Kohlschütter, Dolan Sondhi, Angela Schulz	89
14	Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis 2011 ·European Respiratory Journal ·Michael Wilschanski, L.L. Miller, David Shoseyov, H. Blau, Joseph Rivlin, Micha Aviram, Michael Cohen, S. Armoni, Yasmin Yaakov, (unknown), Malena Cohen‐Cymberknoh, (unknown), A. Reha, Valerie Northcutt, Samit Hirawat, K. Donnelly, Gary Elfring, Temitayo Ajayi, Eitan Kerem	151
15	Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosis 2011 ·Journal of Cystic Fibrosis ·Eitan Kerem, Michael Wilschanski, (unknown), Thea Pugatsch, (unknown), Hannah Blau, Joseph Rivlin, David Shoseyov, A. Reha, S. Constantine, Temitayo Ajayi, Samit Hirawat, Gary Elfring, Stuart W. Peltz, Langdon L. Miller	11
16	Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis 2010 ·American Journal of Respiratory and Critical Care Medicine ·Isabelle Sermet‐Gaudelus, K. De Boeck, Georges Casimir, F. Vermeulen, Teresinha Leal, Agnès Mogenet, Delphine Roussel, Janine Fritsch, L. Hanssens, Samit Hirawat, (unknown), S. Constantine, A. Reha, Temitayo Ajayi, Gary Elfring, Langdon L. Miller	184
17	Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV – Implications for anti-PcrV immunotherapy 2010 ·Microbial Pathogenesis ·Susan V. Lynch, Judith Flanagan, Teiji Sawa, (unknown), Marshall Baek, (unknown), Temitayo Ajayi, Katsunori Yanagihara, Yoichi Hirakata, Shigeru Kohno, Benoît Misset, (unknown), Jeanine P. Wiener-Kronish	29
18	Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU* 2004 ·Critical Care Medicine ·(unknown), Miki Tamura, Leonard R. Allmond, Kiyoshi Moriyama, Temitayo Ajayi, Jeanine P. Wiener-Kronish, Teiji Sawa	57
19	TLR4 signaling is essential for survival in acute lung injury induced by virulent Pseudomonas aeruginosa secreting type III secretory toxins 2004 ·Respiratory Research ·Karine Faure, Teiji Sawa, Temitayo Ajayi, Junichi Fujimoto, Kiyoshi Moriyama, Nobuaki Shime, Jeanine P. Wiener-Kronish	76
20	Lysophospholipase A activity of Pseudomonas aeruginosa type III secretory toxin ExoU 2004 ·Biochemical and Biophysical Research Communications ·Miki Tamura, Temitayo Ajayi, Leonard R. Allmond, Kiyoshi Moriyama, Jeanine P. Wiener-Kronish, Teiji Sawa	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact